COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS

• US 20140274936A1
• Filed: 05/29/2014
• Published: 09/18/2014
• Est. Priority Date: 10/25/2004
• Status: Active Grant

• Current Assignee: Synthonics Incorporated (Synthonics Technologies, Inc.)
• Original Assignee: Synthonics Incorporated (Synthonics Technologies, Inc.)
• Inventors: Piccariello, Thomas, Price, John D., Oberlender, Robert A., Mulhare, Michaela E., Spencer, Mary C., Palmer, Scott B.
• Granted Patent: US 9,624,256 B2
• Time in Patent Office: Days
• US Class Current: 514/43
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/166 having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• CPC Class Codes: A61K 31/295 Iron group metal compounds
• CPC Class Codes: A61K 31/351 not condensed with another ring
• CPC Class Codes: A61K 31/4422 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/55 the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07F 15/02 Iron compounds
• CPC Class Codes: C07F 15/04 Nickel compounds
• CPC Class Codes: C07F 15/045 without a metal-carbon linkage
• CPC Class Codes: C07F 3/00 Compounds containing elements of Groups 2 or 12 of the Periodic Table
• CPC Class Codes: C07F 3/003 without C-Metal linkages
• CPC Class Codes: C07F 3/02 Magnesium compounds
• CPC Class Codes: C07F 3/06 Zinc compounds
• CPC Class Codes: C07H 17/02 Heterocyclic radicals containing only nitrogen as ring hetero atoms

Abstract

A coordination complex having a physiologically acceptable pK_a includes a metal and a biologically active agent. The pK_a of the coordination complex is less than the pK_a of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.

Claims

1. A metal coordination complex of a biologically active moiety and a metal, wherein the biologically active moiety is selected from the group consisting of:

mycophenolate, fingolimod, baclofen, acamprosate, tixocortol, pregabalin, 7-phenyl-2,4,6-hepta-trienal hydroxamic acid, (S)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic acid, eglumegad, (2S,2′

R,3′

R)-2-(2′

,3′

-dicarboxycyclo-propyl)glycine, remacemide, azathioprine, zonisamide, balsalazide, dobutamine, epinephrine, ganciclovir, 6-MP, modafinil, norepinephrine, ribavirin, zoledronic acid, and their derivatives.

2. The complex of claim 1, wherein the metal is selected from:

s-block metals, d-block metals, and p-block metals.

3. A pharmaceutical composition comprising a complex of claim 1 and a pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising a complex of claim 2 and a pharmaceutically acceptable excipient.

5. A method of treating an indication, comprising administering the complex of claim 1 to a patient in need of the biologically active agent for the indication.

6. A method of treating an indication, comprising administering the pharmaceutical composition of claim 3 to a patient in need of the biologically active agent for the indication.

7. A coordination complex comprising a metal and a biologically active agent which is a cannabinoid.

8. The complex of claim 7, wherein the biologically active agent is an antiemetic agent.

9. The complex of claim 7, wherein the biologically active agent is an antiepileptic agent.

10. The complex of claim 7, wherein the metal is selected from:

s-block metals, d-block metals, and p-block metals

11. A pharmaceutical composition comprising a complex of claim 7 and a pharmaceutically acceptable excipient.

12. A method for treating emesis, comprising:

administering the complex of claim 7 to a patient in need of the biologically active agent.

13. A method for treating epilepsy comprising:

administering the complex of claim 7 to a patient in need of the biologically active agent.

14. A method for treating coeliac disease, comprising:

administering the complex of claim 7 to a patient in need of the biologically active agent.

15. A method for treating Alzheimer'"'"'s disease, comprising:

administering the complex of claim 7 to a patient in need of the biologically active agent.

16. A method for treating multiple sclerosis, comprising:

administering the complex of claim 7 to a patient in need of the biologically active agent.

17. A method for treating emesis, comprising:

administering the composition of claim 11 to a patient in need of the biologically active agent.

18. A method for treating epilepsy comprising:

administering the composition of claim 11 to a patient in need of the biologically active agent.

19. A method for treating coeliac disease, comprising:

administering the composition of claim 11 to a patient in need of the biologically active agent.

20. A method for treating Alzheimer'"'"'s disease, comprising:

administering the composition of claim 11 to a patient in need of the biologically active agent.

21. A method for treating multiple sclerosis, comprising:

administering the composition of claim 11 to a patient in need of the biologically active agent.